Rare Kidney Stone Consortium Biobank

NCT02026388

Status RECRUITING
Sponsor Mayo Clinic
Enrollment 2,000 participants

Key Eligibility Criteria

Inclusion (19)

• Diagnosis of primary hyperoxaluria (PH) meeting one or more of the following criteria:

• Liver biopsy documenting alanine-glyoxylate aminotransferase (AGT) activity below the normal reference range confirming PH type 1 OR Liver biopsy documenting glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity below the normal reference range confirming PH type 2

• Molecular genetic analysis (DNA testing) confirming mutations known to cause PH type 1, PH type 2, or PH type 3

• Urinary oxalate excretion of greater than 0.8 mmol/1.73 m2/day (\>70 mg/1.73 m2/day) in the absence of a identifiable causes of secondary hyperoxaluria, including gastrointestinal disease known to cause enteric hyperoxaluria

• A patient in end stage kidney failure, in whom neither a liver biopsy nor mutational analysis are available must have: (a) A plasma oxalate concentration of greater than 60 umol/L and a kidney biopsy confirming extensive oxalate deposits OR (b) Evidence of systemic oxalosis

... and 14 more (see full listing online)

Locations (1 total)

Mayo Clinic, Rochester, Minnesota, United States